Navigation Links
Tianyin Pharmaceutical Co., Inc. Has Four Products Included in China's Essential Drug List
Date:9/10/2009

CHENGDU, China, Sept. 10 /PRNewswire-Asia-FirstCall/ - Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that it has four products included in China's Essential Drug List (EDL) released by the Chinese government on August 18. The four generic products are Azithromycin Dispersible Tablets, Simvastatin Tablets, Hugan Tablets and Xiao Yan Li Dan Capsules and Tablets.

All the drugs in the Essential Drug List will be included in China's basic health insurance catalog with a higher reimbursement percentage. Meanwhile, the pricing of the Essential Drugs will be decided by the governments through public tender at the provincial level. The distribution of Essential Drugs will also be carried out through unified channels by either drug manufacturers or drug distributors. Companies winning the government tenders will have the potential to significantly increase sales while margins on generic and more commonly used drugs will see pricing control from the government.

As a result of this inclusion, management expects the sales of these four drugs could potentially increase from $6.1 million in fiscal year 2009 to approximately $12 million in fiscal year 2010, which ends June 30, 2010.

"The release of China's essential drug list ensures that most rural citizens with comparatively low income will have access to cheap and safe medicines," Dr. Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc., commented. "We view this inclusion as an opportunity to significantly increase revenues generated from these products."

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 40 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    For the Company:
     Allen Tang, Ph.D., MBA, Assistant to the CEO China
     Tel:   +86-158-2122-5642
     Email: Allen.y.tang@gmail.com

    Investors:
     Mr. Matthew Hayden, HC International
     Tel:   +1-561-245-5155
     Email: matt.hayden@hcinternational.net

'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
10. Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
11. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... ... the Snake”: an entertaining and moral-based short story about an unkind snake learning a ... Jr., a husband, father and grandfather who served as a U.S. Marine, U.S. Army ... for children and teens. My goal is to teach kids to use good judgement ...
(Date:8/17/2017)... NC (PRWEB) , ... August 17, 2017 , ... ... dental practice, is adding a new location in Goldsboro, NC to its family ... care that is Riccobene Associates’ trademark starting August 15, 2017. , Riccobene ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... series, proudly announces that it will feature the National Council for Therapeutic Recreation ... for more information. , Established in 1981, NCTRC is a non-profit, international organization ...
(Date:8/17/2017)... MA (PRWEB) , ... August 17, 2017 , ... ... will come together on September 19, 2017 for Anti-Infectives Rx. This off-the-record networking ... B. Martin Conference Center at Harvard Medical School. , Industry leaders and decision ...
(Date:8/17/2017)... GA (PRWEB) , ... August 17, 2017 , ... ... to welcome Dr. Kristi Hebert to its newest location in East ... enthusiastic to have Dr. Hebert come aboard,” said Dr. Mark A. Haber, Georgia Urology’s ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... Aug. 2, 2017   Marshall County Hospital in Benton, Kentucky ... the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for ... kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
Breaking Medicine Technology: